@bedger As of today, I have raised my shareholding past the seven figure mark. I have been happy to accumulate on a downward tack. The lack of liquidity in this stock is self evident. I am somewhat perplexed that the management is taking so long to secure a partner for its recent FDA 510(k) approval in the dental bone and tissue regeneration market...indeed existing competitors and a great deal of inertia might make a breakthrough for Striate+TM a little problematic. I believe Orthocell has the best product, as referenced by the FDA in feedback from KOLs during the application for approval process.... but many weaker products enjoy existing contractual relationships with some powerful distributors . Unlike Australia , the dental market in the US for this type of product , is largely a privately funded. It will take time to build market share and I would not be surprised if Orthocell try to break into this market at a state level, if it gives them better margins and control of their product.
To be clear, I am investing largely for the upside in Cel Gro in nerve repair. Few people have understood that the pricing model in this area will offer exceptional margins because the cost benefit to patients . Following a premium pricing model for porcine collagen scaffolds has proved very lucrative for Vericel (with their MACI product which has outperformed Carticel in an number of specialist applications). A glimpse at their latest presentation gives a taste of what Orthocell shareholders should expect, particularly if we can leverage off our excellent patient data. I think our product is particularly strong when applied to rotator cuff injuries, so I would not be surprised if the Company launched in this area first where it should enjoy competitive advantage.
https://investors.vcel.com/static-files/45de2b52-8937-4b76-bad3-bf61195f3bcfReading through some of the patents, it becomes clear why CelGro could wipe out any competition in this space. The shortcomings of competitor products using rigid hollow tubes and multiple sutures (required with existing methodologies) , not to mention Remplir TM, reportedly almost halving the time taken to achieve nerve regrowth in damage to areas of the peripheral nervous system.....makes me think that Orthocell enjoys a unique advantage. Combine the latter attributes , with good tensile strength, biodegradability and the ability to optimise nerve regrowth within a controlled environment and I believe we have a blockbuster market opportunity . The regulatory pathway in the US is never straightforward, but the revenue opportunities are massive... I had to pinch myself when I realised what the market cap for ORTHOCELL was. Any sign of a proper distribution partner post regulatory approval for Remplir and this could fly . Please do your own research and remember that this stock is highly illiquid until it achieves certain milestones. OP
(20min delay)